KR102432420B1 - (5,6-디하이드로)피리미도[4,5-e]인돌리진 - Google Patents

(5,6-디하이드로)피리미도[4,5-e]인돌리진 Download PDF

Info

Publication number
KR102432420B1
KR102432420B1 KR1020167031029A KR20167031029A KR102432420B1 KR 102432420 B1 KR102432420 B1 KR 102432420B1 KR 1020167031029 A KR1020167031029 A KR 1020167031029A KR 20167031029 A KR20167031029 A KR 20167031029A KR 102432420 B1 KR102432420 B1 KR 102432420B1
Authority
KR
South Korea
Prior art keywords
carboxamide
indolizine
anilino
dihydropyrimido
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167031029A
Other languages
English (en)
Korean (ko)
Other versions
KR20170013866A (ko
Inventor
만 아드리아누스 페트루스 안토니우스 데
로히르 흐리스티안 부에이스만
얀 게라르드 스테렌부르흐
요스트 코르넬리스 마리누스 우이트데하흐
비트 유리 요하네스 페트루스 데
후이도 예니 루돌프 자만
Original Assignee
네덜런즈 트랜슬레이셔널 리서치 센터 비.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 네덜런즈 트랜슬레이셔널 리서치 센터 비.브이. filed Critical 네덜런즈 트랜슬레이셔널 리서치 센터 비.브이.
Publication of KR20170013866A publication Critical patent/KR20170013866A/ko
Application granted granted Critical
Publication of KR102432420B1 publication Critical patent/KR102432420B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020167031029A 2014-04-07 2015-03-30 (5,6-디하이드로)피리미도[4,5-e]인돌리진 Active KR102432420B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP14163734 2014-04-07
EP14163734.8 2014-04-07
EP15153207 2015-01-30
EP15153207.4 2015-01-30
PCT/EP2015/056839 WO2015155042A1 (en) 2014-04-07 2015-03-30 (5,6-dihydro)pyrimido[4,5-e]indolizines

Publications (2)

Publication Number Publication Date
KR20170013866A KR20170013866A (ko) 2017-02-07
KR102432420B1 true KR102432420B1 (ko) 2022-08-17

Family

ID=52774240

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167031029A Active KR102432420B1 (ko) 2014-04-07 2015-03-30 (5,6-디하이드로)피리미도[4,5-e]인돌리진

Country Status (16)

Country Link
US (3) US9856258B2 (enExample)
EP (1) EP3129374B1 (enExample)
JP (1) JP6518690B2 (enExample)
KR (1) KR102432420B1 (enExample)
CN (1) CN106132963B (enExample)
AU (1) AU2015243694B2 (enExample)
BR (1) BR112016022342B1 (enExample)
CA (1) CA2944610C (enExample)
DK (1) DK3129374T3 (enExample)
ES (1) ES2716165T3 (enExample)
HU (1) HUE043108T2 (enExample)
MX (1) MX368767B (enExample)
PL (1) PL3129374T3 (enExample)
PT (1) PT3129374T (enExample)
RU (1) RU2692479C2 (enExample)
WO (1) WO2015155042A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015155042A1 (en) * 2014-04-07 2015-10-15 Netherlands Translational Research Center B.V. (5,6-dihydro)pyrimido[4,5-e]indolizines
US11208696B2 (en) 2015-04-17 2021-12-28 Netherlands Translational Research Center B.V. Prognostic biomarkers for TTK inhibitor chemotherapy
ES2858753T3 (es) * 2016-02-19 2021-09-30 Phoenix Molecular Designs Derivados de 6-oxo-N-(1-(bencil)-1H-pirazol-4-il)-6,7,8,9-tetrahidropirido[3',2':4,5]pirrolo[1,2-a]pirazin-2-carboxamida como inhibidores de cinasa S6 ribosómica (RSK) p90 para el tratamiento del cáncer
CN109311848B (zh) 2016-06-07 2022-02-01 北京加科思新药研发有限公司 可用作shp2抑制剂的新型杂环衍生物
CN106551938B (zh) * 2016-11-26 2017-11-24 广东安诺药业股份有限公司 一种治疗非酒精性脂肪肝的药物及其应用
SMT202400385T1 (it) 2017-03-23 2024-11-15 Jacobio Pharmaceuticals Co Ltd Nuovi derivati eterociclici utili come inibitori di shp2
US20210393623A1 (en) 2018-09-26 2021-12-23 Jacobio Pharmaceuticals Co., Ltd. Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors
EP3924352A4 (en) 2019-02-11 2022-11-16 Phoenix Molecular Designs CRYSTALLINE FORMS OF AN RSK INHIBITOR
KR20240107189A (ko) * 2021-12-15 2024-07-08 신라젠(주) 신생물성 질환 치료에 사용하기 위한 약제학적 병용물
AU2022408915A1 (en) * 2021-12-15 2024-06-27 Sillajen, Inc. Methods of treating neoplastic diseases
US20250049926A1 (en) * 2021-12-15 2025-02-13 Sillajen, Inc. Pharmaceutical compositions comprising modified betacyclodextrins
AU2023228543A1 (en) * 2022-03-04 2024-08-22 Sillajen, Inc. Pharmaceutical combinations for use in the treatment of neoplastic diseases.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009156315A1 (en) 2008-06-26 2009-12-30 Nerviano Medical Sciences S.R.L. Pyrazolo-quinazolines
WO2012101032A1 (en) 2011-01-26 2012-08-02 Nerviano Medical Sciences S.R.L. Tricyclic pyrrolo derivatives, process for their preparation and their use as kinase inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002337142B2 (en) * 2001-09-19 2007-10-11 Aventis Pharma S.A. Indolizines as kinase protein inhibitors
US7482354B2 (en) 2003-05-22 2009-01-27 Nerviano Medical Sciences S.R.L. Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
EP2118102B1 (en) 2006-11-28 2013-06-12 Nerviano Medical Sciences S.r.l. Tricyclic indoles and (4,5-dihydro) indoles
WO2010111406A2 (en) 2009-03-24 2010-09-30 Myriad Pharmaceuticals, Inc. Compounds and therapeutic uses thereof
CN102428086B (zh) 2009-04-29 2014-08-20 内尔维阿诺医学科学有限公司 Cdk抑制剂的盐类
CN103626777B (zh) 2009-07-29 2015-10-21 内尔维阿诺医学科学有限公司 Plk抑制剂的盐类
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
EP2343297A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
US20130303532A1 (en) * 2010-12-17 2013-11-14 Bayer Intellectual Property Gmbh Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment hyperproliferative disorders
JP6523267B2 (ja) 2013-06-24 2019-05-29 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ｆｓｈｒの調節剤としてのイミダゾール化合物及びその使用
WO2015155042A1 (en) * 2014-04-07 2015-10-15 Netherlands Translational Research Center B.V. (5,6-dihydro)pyrimido[4,5-e]indolizines

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009156315A1 (en) 2008-06-26 2009-12-30 Nerviano Medical Sciences S.R.L. Pyrazolo-quinazolines
WO2012101032A1 (en) 2011-01-26 2012-08-02 Nerviano Medical Sciences S.R.L. Tricyclic pyrrolo derivatives, process for their preparation and their use as kinase inhibitors

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Colombo, Riccardo. Cancer Res, 70(24) (2010) 10255-10264.
Jemaa, M. Cell Death and Differentiation (2013) 1532-1545.
Lapenna, Silvia. Nature Reviews: Drug Discovery. (2009) 547-566.
MedicineNet.com (2004). Web<http://www.medterms.com>.
Myeloproliferative disorders: University of Maryland Medical Center. (2016).Web: <http://umm.edu/health/medical/altmed/condition/myeloproliferative-disorders>.

Also Published As

Publication number Publication date
KR20170013866A (ko) 2017-02-07
RU2016141405A3 (enExample) 2018-10-02
BR112016022342A8 (pt) 2021-07-20
PT3129374T (pt) 2019-03-25
BR112016022342A2 (pt) 2017-08-15
EP3129374A1 (en) 2017-02-15
MX2016012997A (es) 2016-12-07
RU2692479C2 (ru) 2019-06-25
JP2017510595A (ja) 2017-04-13
DK3129374T3 (en) 2019-04-08
US20170096432A1 (en) 2017-04-06
WO2015155042A1 (en) 2015-10-15
ES2716165T3 (es) 2019-06-10
JP6518690B2 (ja) 2019-05-22
USRE50082E1 (en) 2024-08-20
CA2944610A1 (en) 2015-10-15
HUE043108T2 (hu) 2019-07-29
AU2015243694B2 (en) 2019-01-17
CN106132963B (zh) 2019-08-06
AU2015243694A1 (en) 2016-11-03
USRE48974E1 (en) 2022-03-15
CN106132963A (zh) 2016-11-16
RU2016141405A (ru) 2018-05-07
CA2944610C (en) 2024-01-09
EP3129374B1 (en) 2018-12-19
MX368767B (es) 2019-10-15
PL3129374T3 (pl) 2019-07-31
BR112016022342B1 (pt) 2022-10-04
US9856258B2 (en) 2018-01-02

Similar Documents

Publication Publication Date Title
KR102432420B1 (ko) (5,6-디하이드로)피리미도[4,5-e]인돌리진
KR101964251B1 (ko) 약학적 화합물
CN108473499B (zh) 新颖的吡唑并嘧啶衍生物
US20200048281A1 (en) Amino-triazolopyridine Compounds and Their Use in Treating Cancer
EP2170827B1 (en) Indolin-2-ones and aza-indolin-2-ones
JP2020196726A (ja) Ｃｄｋ阻害剤としての置換型ヘテロシクリル誘導体
TW201219383A (en) Chemical compounds
AU2021289169B2 (en) Spiro compounds as melanocortin 4 receptor antagonists and uses thereof
AU2014351413B2 (en) Pyrrolopyrrolone derivatives and their use as BET inhibitors
JP6257835B2 (ja) 新規なトリアゾロピリミジノン又はトリアゾロピリジノン誘導体、及びこれらの用途
CN112574255A (zh) 一类基于有机胂的cdk抑制剂及其制备方法和用途
KR20220028075A (ko) 티로신 키나제 비-수용체 1 (tnk1) 억제제 및 그의 용도
IL322876A (en) A disintegrant containing an aryl substituent for CDK12/13, a method for its preparation, as well as a pharmaceutical composition and medical use thereof
HK1231072A1 (en) (5,6-dihydro)pyrimido[4,5-e]indolizines
HK1231072B (zh) (5，6-二氢)嘧啶并[4，5-e]吲嗪
HK40082693A (en) 8-oxo-3-azabicyclo[3.2.1]octane compounds or salts thereof, and preparation method and use thereof
BR112019020309A2 (pt) derivados de quinoxalina e piridopirazina como inibidores de pi3k-beta
HK40082693B (zh) 8-氧-3-氮杂二环[3.2.1]辛烷类化合物或其盐及其制备方法和用途

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20161104

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200327

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20211018

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20220516

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20220810

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20220811

End annual number: 3

Start annual number: 1

PG1601 Publication of registration